Try it on your cases ↗︎Contact us ↗︎
MENU

DIAKWANT® · BIOMARKER QUANTIFICATION

Automated biomarker scoring.See what’s behind the result.

DiaKwant® automates quantification and displays the supporting regions and counts for your review.

CE MARKED UNDER IVDR, CLASS C, IN THE EUResearch Use Only outside the EU

In your supported image management system, move from the slide to quantification without manual preparation.

0 clickThe score runs on the slide, no manual step.
0 annotationNo regions to draw by hand.
0 setupNo calibration before you start.
Whole-slide immunohistochemistry imageTumor-region probability heatmap over the whole-slide imageDiaKwant CPS result and supporting cell counts displayed with the tumor-region heatmap

FROM SLIDE TO SCORE · PD-L1 EXAMPLE

Whole-slide input.

Access the slide for quantification directly through your supported image management system.

DIGITAL ASSAYS

One platform.
Multiple biomarkers.

Explore the biomarkers relevant to your cases. Each assay provides its own measurements and visual outputs to support your review of the score.

PAN‑ORGAN

PD‑L1 CPS / TPS

Review the tumor regions and cell counts behind CPS and TPS to check how the score was calculated.

↗︎BREAST

HER2

Use cell-level measurements of membrane intensity and completeness to support your review of the HER2 score.

↗︎BREAST

Ki‑67

Hotspot and whole-slide proliferation indices.

↗︎BREAST

ER / PR

Interpretable nuclear positivity scores.

↗︎H&E

Mitosis

Detection, classification, heatmaps and hotspot-based mitotic scores.

↗︎

CLINICAL PERSPECTIVE

From scoring
to routine practice.

A testimonial on bringing AI-assisted biomarker quantification into daily pathology practice.

CLINICAL PERSPECTIVE

Hear the clinical perspective.

Watch the conversation on using DiaKwant® in daily pathology practice.

CE marking, in vitro diagnostic medical device

CE-IVDR MARKED, CLASS C

Available for clinical use in the EU.

DiaKwant quantifies and scores PD-L1 CPS & TPS, Mitosis, HER2, Ki-67, ER, PR to assist pathologists on their daily scoring.

Read the announcement ↗︎
25,000+Routine use: more than 25,000 slides analyzed with DiaKwant® in laboratory practice.
1M+Expert annotation: more than one million cells annotated by experts.

EVIDENCE

Evidence behind the score.

View all 14 publications ↗︎

Impact of artificial intelligence assistance on combined PD-L1 scoring on whole immunohistochemical slide image of tumours

PD-L1 blockade has revolutionized cancer therapy, highlighting the need for accurate PD-L1 evaluation using the Combined Positive Score (CPS), which remains…

Read more ↗︎

Impact of DiaKwant HER2 (DiaDeep) Artificial Intelligence (AI) Algorithm in the Evaluation of HER2-Low and HER2-Ultralow Status in Breast Cancer: Data from a Prospective Ring Trial in Greece

HER2 0+, according to CAP HER2 evaluation, or ultralow (UL) expression, is introduced in the assessment of HER2 status in advanced breast cancer (BC), to…

Read more ↗︎

Clinical evaluation of an automated pan-organ combined PD-L1 scoring using artificial intelligence on immunostained whole-slide images

Programmed death-ligand 1 (PD-L1) inhibitors have shown remarkable results in oncology; however, many patients fail to respond, highlighting the need for…

Read more ↗︎

CLUB QUANTI

See how DiaKwant® handles the cases you encounter in your practice.

Bring the evaluation to your own cases: compare DiaKwant® findings with your scoring on your slides.

Apply to Club Quanti ↗︎